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Primary varicella-zoster virus (VZV) infection is a serious illness in immuno-
compromised individuals, and a rapid, sensitive, and reliable assay to identify
high-risk VZV-susceptible patients would be clinically useful. An enzyme-linked
immunosorbent assay (ELISA) for antibody to VZV was compared with the
fluorescent antibody-to-membrane antigen (FAMA) assay and found to be similar
in both sensitivity and specificity. The antibody titers determined by both assays
were also similar. The absence of antibody detected by ELISA correlated with
susceptibility to VZV infection. Because it is simple to perform and has equivalent
sensitivity to FAMA, ELISA should be useful for VZV antibody testing in
diagnostic and research laboratories.
Primary infection with varicella-zoster virus
(VZV) is a serious and often fatal illness in
immunocompromised individuals (5, 6, 13). No-
socomial outbreaks involving both hospital staff
and patients often result in the exposure of a
large number of high-risk individuals whose im-
mune status to VZV is unknown (11, 12). Since
the presence of serum antibody to VZV corre-
lates with immunity to infection (2, 15), a rapid
and reliable serological test for antibody to VZV
would be very useful. By identifying people
susceptible to VZV infection, such an assay
would permit efficient institution of passive anti-
body therapy for immunocompromised patients
and allow appropriate segregation procedures
during nosocomial outbreaks to prevent second-
ary spread of infection (1).
Although several serological assays for VZV
antibody have been developed, inherent difficul-
ties in each of these methods have limited their
usefulness for the routine diagnostic evaluation
of immunity to VZV. For example, both classi-
cal virus neutralization and complement fixation
assays have proven relatively insensitive for
detecting individuals previously infected with
VZV (3, 4, 20). The immune adherence hemag-
glutination assay (IAHA), although more sensi-
tive than complement fixation, may yield a sig-
nificant number of false-negative results (7).
Moreover, cross-reacting antibodies to other
herpesviruses have been noted with IAHA, vi-
rus neutralization, and complement fixation as-
says (18, 22). Fluorescent antibody-to-mem-
brane antigen (FAMA), complement-enhanced
neutralization, and radioimmunoassay (RIA) are
considered the most specific and sensitive meth-
ods for detecting antibody to VZV (8, 9, 16, 21).
However, all of these assays are technically
difficult, and RIA has the added disadvantages
of requiring expensive equipment and presenting
a radiation hazard.
The enzyme-linked immunosorbent assay
(ELISA) is a rapid, sensitive, and reliable meth-
od of assaying antibody to a variety of antigens.
Recently, an ELISA for antibody to VZV has
also been reported, and results have been com-
parable to complement-enhanced neutralization,
complement fixation, and IAHA for detection of
immunoglobulin G (IgG) (7). The results of this
study demonstrate that ELISA is also compara-
ble in sensitivity to FAMA for detection of
antibody to VZV. The absence of antibody
detectable by ELISA appears to correlate with
susceptibility to VZV.
MATERIALS AND METHODS
Tissue culture. Fibroblasts (FS-350Q), derived from
human newborn foreskin, were utilized in passage 13
to 25. Cultures were grown in Eagle basal medium
(BME) supplemented with 10% heat-inactivated (56°C
for 30 min) fetal bovine serum, 50 U of penicillin per
ml, and 50 p.g of streptomycin per ml and maintained
with BME containing 5% fetal bovine serum plus
penicillin and streptomycin. Media for cells seeded
into slide chambers for the performance ofFAMA also
contained 1 ,ug of amphotericin B per ml.
Virus. The strain of VZV (1294) used for these
studies was isolated from the vesicle fluid of a normal
child with uncomplicated varicella. A seed pool of this
strain, passage 7 in FS-350Q, was maintained in liquid
nitrogen in BME containing 20% fetal bovine serum
and 8% dimethyl sulfoxide. Infected whole cells were
utilized for the subculture and cryopreservation of
virus (14, 17). For subculture, infected cells were
inoculated at a ratio of approximately one infected to
three uninfected cells.
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Sera. A total of 144 sera were obtained from normal
and immunocompromised individuals participating in
studies of varicella (13, 19). In this group, 21 cases of
clinical varicella developed. Five of these were further
verified by seroconversion, using both assay systems.
As a positive serological control, a 14-day convales-
cent plasma (ZIP) from an otherwise healthy 18-year-
old woman with zoster was evaluated in each assay
procedure. This serum is negative for antibody for
herpes simplex virus types 1 and 2 and cytomegalovi-
rus (13). All sera were heat inactivated at 56°C for 30
min before testing. Initial screening of sera was at a 1:4
or 1:5 dilution for FAMA and ELISA, respectively.
Subsequent serial twofold dilutions were performed on
sera initially diluted 1:5.
VZV antibody determination. Antibody to VZV
membrane antigen was assayed by a previously report-
ed (13) modification ofFAMA (21). Trypsinized mono-
layers of FS-350Q mixed with VZV-infected cells were
seeded into tissue culture chamber slides. After 24 h,
unfixed cells were exposed to the serum samples
diluted in phosphate-buffered saline (PBS) and then
incubated for 30 min at 37°C with fluorescein-conjugat-
ed goat antiserum to human immunoglobulins (Cappel
Laboratories, Cochranville, Pa., lot 10460). The fluo-
rescein conjugate was absorbed with mouse liver and
FS-350Q and was utilized at a previously determined
optimal dilution of 1:20 to 1:40 in PBS. Slides were
mounted in glycerol buffer (pH 8.5) and inspected for
membrane fluorescence. All samples were encoded for
evaluation.
For ELISA, VZV antigen was prepared from 32-
ounce (ca. 960-ml) bottles of FS-350Q at 72 h after
infection (14). Control antigen was simultaneously
prepared from uninfected cells. The virus-infected and
control monolayers were each washed in Hanks basic
salt solution (HBSS) and then scraped into 20.0 ml of
HBSS. Cells were centrifugated at 250 x g for 20 min
at 4°C and resuspended in 2.5 ml of HBSS. With a
Branson sonifier (model W140) fitted with a microtip,
the cell suspension maintained on ice was sonically
disrupted three times for 30 s at a power setting of 4.
The sonicate was clarified at 250 x g for 20 min at 4°C,
and the supernatant fluid was stored at -20°C for use
as antigen. The optimal dilution of antigen to be used
in further serological testing was determined by block
titration, using a ZIP as well as a normal serum.
Control antigen was utilized in each assay at the same
concentration used for VZV antigen.
ELISA was performed by a method similar to that of
Forghani et al. (7). Briefly, polystyrene microtiter
ELISA plates (Dynatech Laboratories, Windham,
Maine) were labeled with 200 ,ul of VZV and control
antigens diluted in 0.06 M bicarbonate buffer, pH 9.6,
for 24 h at 4°C. Plates labeled in this fashion could be
stored for up to 3 months at 4°C (data not shown).
After storage, the plates were washed with bicarbon-
ate buffer (300 IlI per well), incubated for 30 min at
37°C, and then washed three times with PBS contain-
ing 0.05% Tween 20 (PBST). Test sera were diluted
with PBST and incubated (200 IlI per well) at 37°C for
45 min. Wells were washed three times with PBST and
then incubated with the previously determined optimal
dilution (1:300) of horseradish peroxidase-conjugated
antiserum to human IgG heavy and light chains (Cap-
pel Laboratories) for 30 min at 37°C. After an addition-
al four washes with PBST, enzymatic activity was
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assayed with freshly prepared o-phenylenediamine (1
mg/dl) and 0.003% hydrogen peroxide in distilled wa-
ter. After 30 min of incubation in the dark at room
temperature, the reaction was terminated by the addi-
tion of 25 RI of 8 N H2SO4 to each as well. Optical
density was measured at 490 nm after a 1:3.5 dilution
in PBST.
Statistical methods. Both ELISA and FAMA assays
were performed by using encoded samples. Compari-
son of assay methods was by the least mean square
method, and the correlation of titers was by linear
regression.
RESULTS
ELISA reaction for sera lacking antibody to
VZV. To establish reliable criteria for the
ELISA antibody assay in identifying sera con-
taining antibody to VZV, the variations in color-
imetric reactions of sera lacking VZV antibody
detectable by FAMA were examined. A total of
101 sera with VZV antibody titers of <1:4 by
FAMA were evaluated by ELISA reaction, us-
ing both the VZV and control antigens. The
absorbance readings of these serum samples
diluted 1:5 were determined. The absorbance
(mean ± standard deviation) for sera reacted
with VZV antigen was 0.158 ± 0.085 and for
control antigen was 0.124 ± 0.073. An absor-
bance value of 0.30 was selected as the optical
density to identify sera lacking antibody to VZV
antigen. Similarly, sera with an absorbance of
>0.266 against control antigen were invalid due
to nonspecific reaction. With these criteria, only
3 of 101 sera would have been incorrectly cate-
gorized as containing antibody for VZV, and 9 of
101 sera were invalidated because of nonspecific
reactions to control antigen.
Comparison of ELISA versus FAMA. A total
of 144 sera were evaluated for antibody to VZV
by both FAMA and ELISA. Table 1 summarizes
the results of these studies. A total of 99 sera
were negative by both assays, and 38 sera con-
tained antibody by both assays. Four sera were
negative by ELISA but positive by FAMA, and
three individuals were positive by ELISA but
negative by FAMA. Assuming that FAMA accu-
TABLE 1. Detection of antibody to VZV in 144
sera by ELISA and FAMA
No. of sera with antibody by FAMA
ELISA
Positivea (42) Negative (102)
Reactiveb 38C 3
Nonreactive 4 99
a Titer 2 1:4. Total number of sera is shown within
parentheses.b Titer : 1:5.
c Five patients who had household exposures to
VZV did not develop varicella.
d Twenty patients developed varicella after expo-
sure to VZV.
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FIG. 1. Comparative evaluation of sera for
immunoglobulin activities to VZV virus by ELISA and
FAMA. The linear regression line determined for
antibody-positive sera (r = 0.86) indicates close agree-
ment of these two systems.
rately reflected the presence of VZV antibody in
these 144 sera, ELISA was 90% sensitive and
97% specific.
To further test the specificity of ELISA and
FAMA, ZIP that was reactive at a dilution of
1:64 in both tests was absorbed three times with
either VZV-infected or control FS-350Q cells at
37°C for 30 min. After absorption, the serum
exposed to VZV-infected cells had become neg-
ative by both FAMA and ELISA, whereas the
sera treated with control cells remained reactive
in both assay systems.
To compare antibody titers determined by
ELISA and FAMA, endpoint titrations of 19
sera reactive in both assay systems were per-
formed to examine the antibody determinations
of the two assay methods. As Fig. 1 illustrates,
there was a close correlation of ELISA and
FAMA antibody titers (r = 0.86).
Clinical correlation. Of the 98 patients deter-
mined to be seronegative by ELISA and FAMA,
20 subsequently developed clinical varicella.
Paired acute and convalescent sera were avail-
able from five of these patients, and seroconver-
sion was demonstrated by both assay systems.
Of the 33 ELISA-positive, FAMA-positive sera,
there were 4 household VZV exposures and no
subsequent clinical varicella.
DISCUSSION
Although VZV serology has been performed
by a variety of methods, virus neutralization
with complement enhancement, FAMA, and
RIA assays have to date yielded the most sensi-
tive results. Although these assays are thought
to correlate well with immunity to VZV, they
are time consuming, technically difficult, and
require specialized virological support facilities.
In addition, RIA requires the use of radioactive
materials. A practical, sensitive, and reliable
assay for antibody to VZV is needed for rapid
assessment of immune status to VZV. Our find-
ings and the studies of others suggest that
ELISA fulfills these criteria. Forghani and co-
workers previously reported that ELISA for IgG
antibody to VZV correlated closely to comple-
ment-enhanced virus neutralization but yielded
somewhat higher titers (7). In addition, ELISA
appeared more sensitive than either complement
fixation or IAHA and yielded fewer heterotypic
reactions to other herpesviruses. Hachem et al.
recently reported that ELISA compared favor-
ably with FAMA for detection of IgM antibody
to VZV, but the former yielded somewhat higher
titers (10). Our study demonstrated that ELISA
for immunoglobulin to VZV also compares fa-
vorably with FAMA in both specificity and
sensitivity in identifying sera containing anti-
body to VZV. Moreover, ELISA yielded anti-
body titers similar to those derived by FAMA.
There were seven discrepancies between the
two assays. Three sera were reactive by ELISA
but not by FAMA, and four sera were FAMA
reactive but negative by ELISA. It is not clear
whether these differences represent differences
in the antigens detected by the two assays or
represent the limits of sensitivity of each assay
system.
Previous studies have indicated that antibody
detectable by FAMA correlates with immunity
to VZV. The clinical information available in
this study indicates that seronegativity by both
assay methods correlates with susceptibility to
VZV infection. Too few individuals were avail-
able to confirm whether antibody detectable by
ELISA might be protective, but the correlation
with FAMA suggests that this occurs.
The utility of any serological assay depends
upon its sensitivity and specificity which, in
turn, are reflections of the criteria established to
identify reactive and nonreactive sera. The data
presented in this study represent information
derived as ELISA was implemented in our labo-
ratory. At the inception of this assay, we noted
that 9% of serum samples were eliminated due to
nonspecific reactions to control antigen. This
situation is analogous to the anti-complementary
activity of sera seen in the complement fixation
assay and does not affect test sensitivity or
specificity. As ELISA has subsequently been
performed in our laboratory employing a multi-
channel automated washer, this nonspecificity
has diminished. Thus, none of the last 70 sera
evaluated showed nonspecific reactions to con-
trol antigen.
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A number of unique advantages of ELISA
make it a candidate for use in diagnostic labora-
tories. ELISA reagents can be easily prepared in
the clinical laboratory or may be commercially
available. Once prepared and standardized,
these reagents can be stored for long periods of
time. The antibody assay can be run in as little
as 3 h, employing no elaborate equipment or
unnecessary exposure to radiation. In addition,
the test system can accommodate a large num-
ber of samples, and automated systems are
available. All of these qualities lend themselves
for use in both hospital and epidemiological
settings.
ELISA for immunoglobulin to VZV is a sensi-
tive and specific assay which compares favor-
ably with complement-enhanced virus neutral-
ization and FAMA. The ease of performance
and preparation of reagents are additional ad-
vantages which should permit testing of anti-
body to VZV in diagnostic and research settings.
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